Lung Cancer

AdvanTIG – BGB-A317-A1217-302

The purpose of the study is to compare progression-free survival between Arm A and Arm B as assessed by investigators according to Response Evaluation Criteria in Solid Tumors Version 1.1.

Trial overview


Non-small cell lung cancer


A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.

Eligibility criteria

  • Stage IV Non-Small Cell Lung Cancer with high PDL1 and no driver mutations

Study details

Treatment is Tizlelizumab with an Anti-TIGIT antibody vs Pembrolizumab with placebo vs Tizlelizumab with placebo at a ratio of 5:5:1. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more information regarding this clinical trial click here.


Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.